Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

336.26 23.24 +7.42%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a

Charles River Laboratories International, Inc. 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 26, 2026 · Filed · accepted 9:03 AM ET · Document on sec.gov · Filing index

What changed

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 5, 2026: no comparison — incorporated by reference